                         SEQUENCE LISTING

<110>  ILC Therapeutics Limited
 
<120>  Cancer Treatment

<130>  P227319.WO.01

<150>  GB2010314.9
<151>  2020-07-06

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  166
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-alpha hybrid

<400>  1

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu Ile 
1               5                   10                  15      


Leu Leu Gly Gln Met Gly Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp 
            20                  25                  30          


Arg His Asp Phe Arg Ile Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe 
        35                  40                  45              


Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Met Gln Gln Thr 
    50                  55                  60                  


Phe Asn Leu Phe Ser Thr Lys Asn Ser Ser Ala Ala Trp Asp Glu Thr 
65                  70                  75                  80  


Leu Leu Glu Lys Phe Tyr Ile Glu Leu Phe Gln Gln Met Asn Asp Leu 
                85                  90                  95      


Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met 
            100                 105                 110         


Asn Glu Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile Thr 
        115                 120                 125             


Leu Tyr Leu Ile Glu Arg Lys Tyr Ser Pro Cys Ala Trp Glu Val Val 
    130                 135                 140                 


Arg Ala Glu Ile Met Arg Ser Leu Ser Phe Ser Thr Asn Leu Gln Lys 
145                 150                 155                 160 


Arg Leu Arg Arg Lys Asp 
                165     


<210>  2
<211>  507
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  IFN-alpha hybrid - E. coli codon optimised

<400>  2
atgtgtgatc tgccgcagac ccatagcctg ggtaatcgtc gtgcactgat tctgctgggt       60

cagatgggtc gtattagccc gtttagctgt ctgaaagatc gtcatgattt tcgtattccg      120

caagaggaat ttgatggcaa ccagtttcag aaagcacagg caattagcgt tctgcatgaa      180

atgatgcagc agacctttaa cctgtttagc accaaaaata gcagcgcagc atgggatgaa      240

accctgctgg aaaaattcta tatcgaactg tttcagcaga tgaacgatct ggaagcatgt      300

gttattcaag aagttggcgt tgaagaaaca ccgctgatga atgaagatag cattctggca      360

gtgaaaaaat actttcagcg cattaccctg tatctgatcg aacgtaaata tagcccgtgt      420

gcatgggaag ttgttcgtgc agaaattatg cgtagcctga gctttagcac caatctgcaa      480

aaacgtctgc gtcgcaaaga ttaataa                                          507


<210>  3
<211>  166
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Consensus backbone sequence of all 12 alpha-interferons

<400>  3

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu Ile 
1               5                   10                  15      


Leu Leu Gly Gln Met Gly Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp 
            20                  25                  30          


Arg His Asp Phe Arg Ile Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe 
        35                  40                  45              


Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Met Gln Gln Thr 
    50                  55                  60                  


Phe Asn Leu Phe Ser Thr Glu Asn Ser Ser Ala Ala Trp Glu Gln Thr 
65                  70                  75                  80  


Leu Leu Glu Lys Phe Ser Ile Glu Leu Phe Gln Gln Met Asn Asp Leu 
                85                  90                  95      


Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met 
            100                 105                 110         


Asn Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr 
        115                 120                 125             


Leu Tyr Leu Ile Glu Arg Lys Tyr Ser Pro Cys Ala Trp Glu Val Val 
    130                 135                 140                 


Arg Ala Glu Ile Met Arg Ser Leu Ser Phe Ser Thr Asn Leu Gln Lys 
145                 150                 155                 160 


Arg Leu Arg Arg Lys Asp 
                165     


